The next wave of CLL research is moving beyond a standard one-year fixed duration. Ongoing studies now use Minimal Residual Disease (MRD) results to tailor treatment length, personalizing care by potentially shortening, extending, or adding therapies based on a patient's individual depth of response.

In metastatic colorectal cancer, clinicians are using ctDNA MRD testing to help guide the decision to stop immunotherapy. For patients who have been on treatment for 1.5-2 years with a complete or durable radiographic response, a negative ctDNA result provides an additional layer of confidence to discontinue therapy.

A key conceptual shift is viewing ctDNA not as a statistical risk marker, but as direct detection of molecular residual disease (MRD). This framing, similar to how a CT scan identifies metastases, explains its high positive predictive value and justifies its use in making critical treatment decisions.

While the DYNAMIC-2 trial confirmed a ctDNA-guided approach is non-inferior for Stage II colon cancer and reduces chemotherapy use, the DYNAMIC-3 trial in Stage III patients failed to prove non-inferiority for de-escalation or show benefit for escalation. This highlights a critical, stage-dependent limitation in using current MRD assays.

Minimal Residual Disease (MRD) negativity is now recognized by regulators as a surrogate endpoint in oncology. Because it is considered 'reasonably likely to predict progression-free survival,' this shift allows drug developers to use MRD data to support accelerated approval pathways, expediting the availability of new therapies.

Emerging data from major trials shows that ctDNA clearance during neoadjuvant therapy and negative post-surgical MRD status are strong predictors of improved survival. MRD positivity, in contrast, is associated with worse biology and rapid progression.

Both experts advocate shifting immune cell engager use from late-stage, high-burden cancer to a minimal residual disease (MRD) setting. Treating a low tumor load maximizes the effector-to-target ratio, enhances efficacy, and significantly reduces side effects, potentially moving these therapies to first-line combinations.

Clinical trial data provides a clear directive for using MRD testing. The DYNAMIC study showed that for stage 2 colon cancer, a ctDNA-guided approach halved chemotherapy use with identical outcomes. In contrast, the DYNAMIC-3 study found that de-escalating chemo for high-risk stage 3 patients based on a negative ctDNA result led to worse outcomes.

Despite the excellent prognosis associated with a negative post-operative MRD test, oncologists are not yet comfortable omitting adjuvant chemotherapy for younger, high-risk stage II colon cancer patients. The current data is not considered sufficient to justify de-escalation based on a negative ctDNA result alone outside of a clinical trial setting.